REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in four upcoming investor conferences.
The Jefferies London Healthcare Conference (London, UK)
The Stifel 2023 Healthcare Conference (New York, NY)
The Stephens Annual Investment Conference (Nashville, TN)
The 14th Annual Craig-Hallum Alpha Select Conference (New York, NY)
Live webcasts of each fireside chat will be available on the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay of each fireside chat will be archived for 90 days following the presentation date.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Lauren Musto
(781) 572-1147
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.11 |
| Daily Change: | -0.01 -0.47 |
| Daily Volume: | 553,215 |
| Market Cap: | US$171.710M |
April 01, 2025 February 27, 2025 January 16, 2025 November 14, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
